NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 2.2022

Overview

Journal J Natl Compr Canc Netw

Specialty Oncology

Date 2022 Nov 9

PMID 36351335

Authors

Margaret von Mehren

John M Kane

Richard F Riedel

Jason K Sicklick

Seth M Pollack

Mark Agulnik

Marilyn M Bui

Janai Carr-Ascher

Edwin Choy

Mary Connelly

Sarah Dry

Kristen N Ganjoo

Ricardo J Gonzalez

Ashley Holder

Jade Homsi

Vicki Keedy

Ciara M Kelly

Edward Kim

David Liebner

Martin McCarter

Sean V McGarry

Nathan W Mesko

Christian Meyer

Alberto S Pappo

Amanda M Parkes

Ivy A Petersen

Matthew Poppe

Scott Schuetze

Jacob Shabason

Matthew B Spraker

Melissa Zimel

Mary Anne Bergman

Hema Sundar

Lisa E Hang

Affiliations

Soon will be listed here.

Abstract

Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes. The NCCN Guidelines for GIST provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with these tumors. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised systemic therapy options for unresectable, progressive, or metastatic GIST based on mutational status, and updated recommendations for the management of GIST that develop resistance to specific tyrosine kinase inhibitors.

Citing Articles

Trends and Financial Burden of Gastrointestinal Stromal Tumors in the United States: A Comprehensive Analysis of United States Hospitalizations.

Sonaiya S, Patel R, Parikh C, Dahiya D, Yagnik K, Barnechea Alvarado N Gastroenterology Res. 2025; 18(1):12-22.

PMID: 40051888 PMC: 11882225. DOI: 10.14740/gr2009.

Case report: Clinical and molecular features of renal gastrointestinal tumor.

Makker S, Rammal R, Gu P, Dalbagni G, Al-Ahmadie H, Agaram N Front Oncol. 2025; 15:1508600.

PMID: 40018405 PMC: 11865245. DOI: 10.3389/fonc.2025.1508600.

Inflammatory biomarker correlations and prognosis in high-risk gastrointestinal stromal tumor patients: a multicenter retrospective analysis.

Wang T, Qi L, Zhao Y, Ma X, Li T BMC Gastroenterol. 2025; 25(1):119.

PMID: 40011800 PMC: 11863871. DOI: 10.1186/s12876-025-03710-8.

Case report: One case of precise resection of gastric glomus tumor by gastroscopy combined with laparoscopy.

Yang X, Guo Y, Yan X, Xu B, Cui Z, Guo Z Front Oncol. 2025; 14():1501442.

PMID: 39839772 PMC: 11746095. DOI: 10.3389/fonc.2024.1501442.

Interpretable machine learning model based on CT semantic features and radiomics features to preoperatively predict Ki-67 expression in gastrointestinal stromal tumors.

Wang Y, Bai G, Liu Y, Huang M, Chen W, Wang F Sci Rep. 2024; 14(1):29336.

PMID: 39592767 PMC: 11599915. DOI: 10.1038/s41598-024-80978-y.

References

Belinsky M, Rink L, Cai K, Capuzzi S, Hoang Y, Chien J . Somatic loss of function mutations in neurofibromin 1 and MYC associated factor X genes identified by exome-wide sequencing in a wild-type GIST case. BMC Cancer. 2015; 15:887. PMC: 4641358. DOI: 10.1186/s12885-015-1872-y. View

Debiec-Rychter M, Dumez H, Judson I, Wasag B, Verweij J, Brown M . Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2004; 40(5):689-95. DOI: 10.1016/j.ejca.2003.11.025. View

DeMatteo R, Heinrich M, El-Rifai W, Demetri G . Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum Pathol. 2002; 33(5):466-77. DOI: 10.1053/hupa.2002.124122. View

Schoffski P, Reichardt P, Blay J, Dumez H, Morgan J, Ray-Coquard I . A phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors. Ann Oncol. 2010; 21(10):1990-1998. DOI: 10.1093/annonc/mdq076. View

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S . Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279(5350):577-80. DOI: 10.1126/science.279.5350.577. View

Lee J, Shin S, Choe E, Kim J, Hyung W, Kim H . Tropomyosin-Related Kinase Fusions in Gastrointestinal Stromal Tumors. Cancers (Basel). 2022; 14(11). PMC: 9179593. DOI: 10.3390/cancers14112659. View

Ma G, Murphy J, Martinez M, Sicklick J . Epidemiology of gastrointestinal stromal tumors in the era of histology codes: results of a population-based study. Cancer Epidemiol Biomarkers Prev. 2014; 24(1):298-302. PMC: 4294949. DOI: 10.1158/1055-9965.EPI-14-1002. View

Charo L, Burgoyne A, Fanta P, Patel H, Chmielecki J, Sicklick J . A Novel Fusion in Gastrointestinal Stromal Tumor Guides Adjuvant Treatment Decision-Making During Pregnancy. J Natl Compr Canc Netw. 2018; 16(3):238-242. PMC: 6053908. DOI: 10.6004/jnccn.2017.7039. View

Jones R, Serrano C, von Mehren M, George S, Heinrich M, Kang Y . Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial. Eur J Cancer. 2021; 145:132-142. PMC: 9518931. DOI: 10.1016/j.ejca.2020.12.008. View

10.

Heinrich M, Rankin C, Blanke C, Demetri G, Borden E, Ryan C . Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol. 2017; 3(7):944-952. PMC: 5727908. DOI: 10.1001/jamaoncol.2016.6728. View

11.

Patel N, Benipal B . Incidence of Gastrointestinal Stromal Tumors in the United States from 2001-2015: A United States Cancer Statistics Analysis of 50 States. Cureus. 2019; 11(2):e4120. PMC: 6478492. DOI: 10.7759/cureus.4120. View

12.

Ganjoo K, Villalobos V, Kamaya A, Fisher G, Butrynski J, Morgan J . A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib. Ann Oncol. 2013; 25(1):236-40. PMC: 4271129. DOI: 10.1093/annonc/mdt484. View

13.

Schuetze S, Bolejack V, Thomas D, von Mehren M, Patel S, Samuels B . Association of Dasatinib With Progression-Free Survival Among Patients With Advanced Gastrointestinal Stromal Tumors Resistant to Imatinib. JAMA Oncol. 2018; 4(6):814-820. PMC: 6145709. DOI: 10.1001/jamaoncol.2018.0601. View

14.

Desai J, Shankar S, Heinrich M, Fletcher J, Fletcher C, Manola J . Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors. Clin Cancer Res. 2007; 13(18 Pt 1):5398-405. DOI: 10.1158/1078-0432.CCR-06-0858. View

15.

Patel S, Zalcberg J . Optimizing the dose of imatinib for treatment of gastrointestinal stromal tumours: lessons from the phase 3 trials. Eur J Cancer. 2008; 44(4):501-9. DOI: 10.1016/j.ejca.2007.11.021. View

16.

Park S, Ryu M, Ryoo B, Im S, Kwon H, Lee S . Sorafenib in patients with metastatic gastrointestinal stromal tumors who failed two or more prior tyrosine kinase inhibitors: a phase II study of Korean gastrointestinal stromal tumors study group. Invest New Drugs. 2012; 30(6):2377-83. DOI: 10.1007/s10637-012-9795-9. View

17.

Miettinen M, Wang Z, Sarlomo-Rikala M, Osuch C, Rutkowski P, Lasota J . Succinate dehydrogenase-deficient GISTs: a clinicopathologic, immunohistochemical, and molecular genetic study of 66 gastric GISTs with predilection to young age. Am J Surg Pathol. 2011; 35(11):1712-21. PMC: 3193596. DOI: 10.1097/PAS.0b013e3182260752. View

18.

Heinrich M, Maki R, Corless C, Antonescu C, Harlow A, Griffith D . Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008; 26(33):5352-9. PMC: 2651076. DOI: 10.1200/JCO.2007.15.7461. View

19.

Patrikidou A, Domont J, Chabaud S, Ray-Coquard I, Coindre J, Bui-Nguyen B . Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group. Eur J Cancer. 2015; 52:173-80. DOI: 10.1016/j.ejca.2015.10.069. View

20.

Goodman V, Rock E, Dagher R, Ramchandani R, Abraham S, Gobburu J . Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma. Clin Cancer Res. 2007; 13(5):1367-73. DOI: 10.1158/1078-0432.CCR-06-2328. View